Chapter 2 . 1 Reduced biological activity of recombinant IFN-β and treatment response IFN-β bioactivity measurement in MS : feasibility for routine clinical practice
暂无分享,去创建一个
H. Vrenken | C. Polman | A. Peña | J. Killestein | J. Kragt | A. Bertolotto | F. Gilli | M. Caldano | A. Visser | A. Kok | H. Guzel | L. Voort | C. Oudejans | M. Sombekke | J. M. Nielsen | C. B. M. Oudejan | J. Crusi
[1] K. Schmierer,et al. Assessing treatment response to interferon-β , 2014, Neurology.
[2] Pablo Villoslada,et al. Multiple Sclerosis Susceptibility Genes: Associations with Relapse Severity and Recovery , 2013, PloS one.
[3] J. Havla,et al. Bridging, switching or drug holidays – how to treat a patient who stops natalizumab? , 2013, Therapeutics and clinical risk management.
[4] P. Calabresi,et al. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. , 2013, Brain : a journal of neurology.
[5] Hans-Jürgen Thiesen,et al. MicroRNA Expression Changes during Interferon-Beta Treatment in the Peripheral Blood of Multiple Sclerosis Patients , 2013, International journal of molecular sciences.
[6] R. Reuss. PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update , 2013, Biologics : targets & therapy.
[7] T. Olsson,et al. Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity , 2013, Proceedings of the National Academy of Sciences.
[8] F. Barkhof,et al. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis , 2013, Multiple sclerosis.
[9] L. Steinman,et al. Type I Interferons: Beneficial in Th1 and Detrimental in Th17 Autoimmunity , 2013, Clinical Reviews in Allergy & Immunology.
[10] M. Kvarnström,et al. Longitudinal interferon-β effects in multiple sclerosis: Differential regulation of IL-10 and IL-17A, while no sustained effects on IFN-γ, IL-4 or IL-13 , 2013, Journal of the Neurological Sciences.
[11] G. Esendagli,et al. Evaluation of Th17-related cytokines and receptors in multiple sclerosis patients under interferon beta-1 therapy , 2013, Journal of Neuroimmunology.
[12] S. Dhib-jalbut,et al. Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study , 2013, Journal of Neuroimmunology.
[13] A. Vulto,et al. Interchangeability, immunogenicity and biosimilars , 2012, Nature Biotechnology.
[14] D. Arnold,et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. , 2012, The New England journal of medicine.
[15] F. Deisenhammer,et al. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial , 2012, Neurology.
[16] L. Steinman,et al. Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS , 2012, Neurology.
[17] Bernhard Hemmer,et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. , 2012, The New England journal of medicine.
[18] H. Wiendl,et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort , 2012, Neurology.
[19] Meena Subramanyam,et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. , 2012, The New England journal of medicine.
[20] J. Hillert,et al. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice , 2012, Multiple sclerosis.
[21] A. Lutterotti,et al. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation , 2012, Multiple sclerosis.
[22] Joanne L. Jones,et al. Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis , 2012, Expert review of neurotherapeutics.
[23] A. Reder,et al. Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis , 2012, Journal of the Neurological Sciences.
[24] D. Goodin,et al. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial , 2012, Multiple sclerosis.
[25] X. Montalban,et al. Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. , 2011, Clinical immunology.
[26] D. Paty,et al. Interferon beta-1b is effective in relapsing-remitting multiple-sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial , 2011, Neurology.
[27] A. P. Ross,et al. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis , 2011, International journal of clinical practice.
[28] C. Polman,et al. IL-7 Promotes TH1 Development and Serum IL-7 Predicts Clinical Response to Interferon-β in Multiple Sclerosis , 2011, Science Translational Medicine.
[29] L. Steinman,et al. Interferon-β exacerbates Th17-mediated inflammatory disease. , 2011, Trends in immunology.
[30] M. Sá,et al. Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works. , 2011, Arquivos de neuro-psiquiatria.
[31] R. Rudick,et al. Excessive Biologic Response to IFNβ Is Associated with Poor Treatment Response in Patients with Multiple Sclerosis , 2011, PloS one.
[32] A. Bertolotto,et al. One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients , 2011, Journal of Neurology.
[33] H. Lockstone,et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses , 2011, Nature Immunology.
[34] P. Sørensen,et al. Neutralizing antibodies against interferon-β do not predispose antibodies against natalizumab , 2011, Neurology.
[35] P. Van Der Valk,et al. Multiple sclerosis as an “Inside‐out” disease , 2010, Annals of neurology.
[36] F. Barkhof,et al. Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS , 2010, Neurology.
[37] K. Vandenbroeck,et al. Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis. , 2010, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[38] H. Hartung,et al. Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta. , 2010, Archives of neurology.
[39] M. Bojar,et al. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis , 2010, Multiple sclerosis.
[40] M. Crow. Type I interferon in organ-targeted autoimmune and inflammatory diseases , 2010, Arthritis research & therapy.
[41] E. Urcelay,et al. IFN-beta pharmacogenomics in multiple sclerosis. , 2010, Pharmacogenomics.
[42] Jacqueline A Palace,et al. Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. , 2010, Archives of neurology.
[43] Bernhard Hemmer,et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis , 2010, The Lancet Neurology.
[44] S. Gregory,et al. Alternative splicing in multiple sclerosis and other autoimmune diseases , 2010, RNA biology.
[45] G. Giovannoni,et al. Multiple sclerosis: risk factors, prodromes, and potential causal pathways , 2010, The Lancet Neurology.
[46] G. Ebers,et al. Multiple sclerosis, vitamin D, and HLA-DRB1*15 , 2010, Neurology.
[47] AJ Thompson,et al. Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components? , 2010, Multiple sclerosis.
[48] H. Søndergaard,et al. Breakthrough disease during interferon-β therapy in MS , 2010, Neurology.
[49] G. Gronseth,et al. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis , 2010, Neurology.
[50] David Arteta,et al. Analysis of multiple candidate genes in association with phenotypes of multiple sclerosis , 2010, Multiple sclerosis.
[51] M. Brown,et al. Multiple Sclerosis Susceptibility-Associated SNPs Do Not Influence Disease Severity Measures in a Cohort of Australian MS Patients , 2010, PloS one.
[52] Lawrence Steinman,et al. T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis , 2010, Nature Medicine.
[53] Ludwig Kappos,et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.
[54] Ludwig Kappos,et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.
[55] F. Barkhof,et al. MRI criteria for MS in patients with clinically isolated syndromes , 2010, Neurology.
[56] A. Lovett-racke,et al. The mechanism of action of glatiramer acetate treatment in multiple sclerosis , 2010, Neurology.
[57] R. Rudick,et al. Gray-matter injury in multiple sclerosis. , 2009, New England Journal of Medicine.
[58] A. Svejgaard,et al. Identification of new sensitive biomarkers for the in vivo response to interferon‐β treatment in multiple sclerosis using DNA‐array evaluation , 2009, European journal of neurology.
[59] X. Montalban,et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. , 2009, Brain : a journal of neurology.
[60] S. Ropele,et al. Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study , 2009, Multiple sclerosis.
[61] C. Pozzilli,et al. One‐year MRI scan predicts clinical response to interferon beta in multiple sclerosis , 2009, European journal of neurology.
[62] M. Freedman. ‘Time is brain’ also in multiple sclerosis , 2009, Multiple sclerosis.
[63] Wei Hu,et al. The pathological spectrum of CNS inflammatory demyelinating diseases , 2009, Seminars in Immunopathology.
[64] F. Sellebjerg,et al. Absence of MxA induction by interferon β in patients with MS reflects complete loss of bioactivity , 2009, Neurology.
[65] Arcadi Navarro,et al. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. , 2009, Archives of neurology.
[66] J. Grutters,et al. Variation in IL7R predisposes to sarcoid inflammation , 2009, Genes and Immunity.
[67] J Sastre-Garriga,et al. Measures in the first year of therapy predict the response to interferon β in MS , 2009, Multiple sclerosis.
[68] Ludwig Kappos,et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci , 2009, Nature Genetics.
[69] E. Urcelay,et al. Glypican 5 is an interferon-beta response gene: a replication study , 2009, Multiple sclerosis.
[70] A. Sadovnick,et al. Risk alleles for multiple sclerosis in multiplex families , 2009, Neurology.
[71] A. Millonig,et al. High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study , 2009, Multiple sclerosis.
[72] R. Gold,et al. Variation in the IL7RA and IL2RA genes in German multiple sclerosis patients. , 2009, Journal of autoimmunity.
[73] Michael R. Johnson,et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. , 2009, Human molecular genetics.
[74] J. Frederiksen,et al. Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon‐β , 2009, European journal of neurology.
[75] M. Ramanathan,et al. Genomic effects of once-weekly, intramuscular interferon-β1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients , 2008, Journal of Neuroimmunology.
[76] J. Oger,et al. The implications of immunogenicity for protein-based multiple sclerosis therapies , 2008, Journal of the Neurological Sciences.
[77] C. Duijn,et al. Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis , 2008, Nature Genetics.
[78] A. Alcina,et al. The T244I variant of the interleukin-7 receptor-alpha gene and multiple sclerosis. , 2008, Tissue antigens.
[79] P. Sørensen,et al. Is the treatment effect of IFN-β restored after the disappearance of neutralizing antibodies? , 2008, Multiple sclerosis.
[80] À. Rovira,et al. Very early scans for demonstrating dissemination in time in multiple sclerosis , 2008, Multiple Sclerosis.
[81] E. Pérez-Pampín,et al. Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis. , 2008, Arthritis and rheumatism.
[82] R. Lucas. Faculty Opinions recommendation of Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis. , 2008 .
[83] C. Polman,et al. Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients , 2008, PloS one.
[84] P. Valentino,et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis , 2008, Neurology.
[85] F. Holsboer,et al. Variant form of STAT4 is associated with primary Sjögren's syndrome , 2008, Genes and Immunity.
[86] Pablo Villoslada,et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. , 2008, Archives of neurology.
[87] L. Peltonen,et al. Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations , 2008, Journal of Medical Genetics.
[88] K. Vandenbroeck,et al. IL7RA polymorphisms and susceptibility to multiple sclerosis. , 2008, The New England journal of medicine.
[89] À. Rovira,et al. Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients , 2008, Multiple sclerosis.
[90] P. Carrieri,et al. Interleukin-10 and Interleukin-12 Modulation in Patients with Relapsing-Remitting Multiple Sclerosis on Therapy with Interferon-beta 1a: Differences in Responders and Non Responders , 2008, Immunopharmacology and immunotoxicology.
[91] L. Milani,et al. An insertion-deletion polymorphism in the interferon regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. , 2007, Human molecular genetics.
[92] J. Haselkorn,et al. Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model , 2007, Multiple sclerosis.
[93] A. Pachner. Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology , 2007, Neurology.
[94] J. Hillert,et al. In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.
[95] Silke Schmidt,et al. Interleukin 7 receptor α chain ( IL7R ) shows allelic and functional association with multiple sclerosis , 2007, Nature Genetics.
[96] M. Chiarini,et al. IFNβ bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays , 2007, Journal of Neuroimmunology.
[97] S. Gabriel,et al. Risk alleles for multiple sclerosis identified by a genomewide study. , 2007, The New England journal of medicine.
[98] Marco Rovaris,et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study , 2007, The Lancet Neurology.
[99] A. Syvänen,et al. Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. , 2007, Arthritis and rheumatism.
[100] A. Noronha,et al. Guidelines on use of anti‐IFN‐B antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐B antibodies in multiple sclerosis , 2007, European journal of neurology.
[101] Ludwig Kappos,et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring , 2007, The Lancet Neurology.
[102] L. Kappos,et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS , 2007, Neurology.
[103] A. Bertolotto,et al. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. , 2007, Journal of immunological methods.
[104] D. Goodin,et al. Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: [RETIRED] , 2007, Neurology.
[105] K. Honda,et al. Cooperation between MyD88 and TRIF pathways in TLR synergy via IRF5 activation. , 2007, Biochemical and biophysical research communications.
[106] M. Krumbholz,et al. Multiple sclerosis: Relating MxA transcription to anti-interferon-β-neutralizing antibodies , 2007, Neurology.
[107] M. Suoniemi,et al. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity , 2007, Multiple sclerosis.
[108] K. Bendtzen,et al. Are ex vivo neutralising antibodies against IFN-β always detrimental to therapeutic efficacy in multiple sclerosis? , 2007, Multiple sclerosis.
[109] G. Giovannoni,et al. Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis , 2007, Multiple sclerosis.
[110] P. Sørensen,et al. Neutralizing antibodies hamper IFNβ bioactivity and treatment effect on MRI in patients with MS , 2006, Neurology.
[111] L. Kappos,et al. Infusion-related hypersensitivity reactions during natalizumab treatment , 2006, Neurology.
[112] P. Sørensen. Neutralising antibodies to interferon-β–measurement, clinical relevance, and management , 2006, Journal of Neurology.
[113] W. Valdar,et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study , 2006, The Lancet Neurology.
[114] H. Link,et al. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: An update on methodology and clinical usefulness , 2006, Journal of Neuroimmunology.
[115] H P Hartung,et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes , 2006, Neurology.
[116] P. Sørensen,et al. Persistence of neutralizing antibodies after discontinuation of IFNβ therapy in patients with relapsing-remitting multiple sclerosis , 2006, Multiple sclerosis.
[117] A. Lutterotti,et al. Interferon-β antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies , 2006, Journal of Neuroimmunology.
[118] Marta E Alarcón-Riquelme,et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus , 2006, Nature Genetics.
[119] Christian Confavreux,et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. , 2006, The New England journal of medicine.
[120] Ludwig Kappos,et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.
[121] V. Tomassini,et al. Predictors of long–term clinical response to interferon beta therapy in relapsing multiple sclerosis , 2006, Journal of Neurology.
[122] K. Narayan,et al. Multiplex analysis of expression of three IFNβ-induced genes in antibody-positive MS patients , 2006, Neurology.
[123] X. Montalban,et al. Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patients , 2006, Annals of neurology.
[124] A. Bertolotto,et al. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1 , 2006, Multiple sclerosis.
[125] A. Bertolotto,et al. Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments , 2005, Neurological Sciences.
[126] V. Tomassini,et al. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience , 2005, Neurological Sciences.
[127] Michael Hutchinson,et al. Pharmacogenomics of responsiveness to interferon IFN‐β treatment in multiple sclerosis: A genetic screen of 100 type I interferon‐inducible genes , 2005, Clinical pharmacology and therapeutics.
[128] S. Reingold,et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.
[129] T. Decker,et al. The Yin and Yang of type I interferon activity in bacterial infection , 2005, Nature Reviews Immunology.
[130] K. Tyler,et al. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. , 2005, The New England journal of medicine.
[131] S. Atlas,et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. , 2005, The New England journal of medicine.
[132] P. Rutgeerts,et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. , 2005, The New England journal of medicine.
[133] A. Thompson,et al. The distribution of magnetic resonance imaging response to interferonβ–1b in multiple sclerosis , 2005, Journal of Neurology.
[134] P. Sørensen,et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy , 2005, Neurology.
[135] L. Kappos,et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. , 2005 .
[136] Katherine E. M. Hoops,et al. Two Discrete Promoters Regulate the Alternatively Spliced Human Interferon Regulatory Factor-5 Isoforms , 2005, Journal of Biological Chemistry.
[137] J. Kere,et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. , 2005, American journal of human genetics.
[138] A. Bertolotto,et al. Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis , 2005, Journal of Neuroimmunology.
[139] A. Lutterotti,et al. Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity , 2004, Multiple sclerosis.
[140] F. Barkhof,et al. Gender-related association between the TGFB1+869 polymorphism and multiple sclerosis. , 2004, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[141] A. Bertolotto,et al. Cotugno and cerebrospinal fluid , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[142] A. Bertolotto,et al. Neutralizing antibodies reduce the efficacy of βIFN during treatment of multiple sclerosis , 2004, Neurology.
[143] H. Schellekens,et al. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis , 2004, Journal of Neurology.
[144] M. Calabrese,et al. The clinical impact of interferon beta antibodies in relapsing-remitting MS , 2004, Journal of Neurology.
[145] D. Goodin,et al. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. , 2004, Neurology.
[146] R. Proia,et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 , 2004, Nature.
[147] W. Haupt,et al. Long‐term persisting interferon beta‐1b neutralizing antibodies after discontinuation of treatment , 2004, Acta neurologica Scandinavica.
[148] Jingwu Z. Zhang,et al. Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis. , 2003, Brain : a journal of neurology.
[149] M. Sela,et al. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy , 2003, Multiple sclerosis.
[150] A. Pachner. An improved ELISA for screening for neutralizing anti-IFN-β antibodies in MS patients , 2003, Neurology.
[151] K. Bendtzen. [Immunogenicity of biopharmaceuticals. Experiences with beta-interferon, EPO and anti-TNF]. , 2003, Ugeskrift for læger.
[152] V. Tomassini,et al. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years , 2003, Journal of the Neurological Sciences.
[153] G. Giovannoni. Strategies to treat and prevent the development of neutralizing anti-interferon-β antibodies , 2003, Neurology.
[154] P. Sørensen,et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis , 2003, The Lancet.
[155] S. Vukusic,et al. Clinical characteristics of responders to interferon therapy for relapsing MS , 2003, Neurology.
[156] C. Pozzilli,et al. Pharmacological methods to overcome IFN-β antibody formation in the treatment of multiple sclerosis , 2003, Expert opinion on investigational drugs.
[157] S. Grossberg,et al. Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity. , 2003, Journal of immunological methods.
[158] L. Staudt,et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. , 2003, Brain : a journal of neurology.
[159] A. Thompson,et al. New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes , 2003, Annals of neurology.
[160] Virginia Pascual,et al. Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood , 2003, The Journal of experimental medicine.
[161] J. Haines,et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. , 2003, American journal of human genetics.
[162] R. Lindberg,et al. Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients , 2003, Neurology.
[163] J. Wolinsky. The diagnosis of primary progressive multiple sclerosis , 2003, Journal of the Neurological Sciences.
[164] Ash A. Alizadeh,et al. Individuality and variation in gene expression patterns in human blood , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[165] David H. Miller,et al. A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.
[166] H. Hartung,et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial , 2002, The Lancet.
[167] F. Munschauer,et al. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis , 2002, Journal of neurology, neurosurgery, and psychiatry.
[168] Carlos Nos,et al. Assessment of different treatment failure criteria in a cohort of relapsing–remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials , 2002, Annals of neurology.
[169] Andreas Radbruch,et al. Humoral immunity and long-lived plasma cells. , 2002, Current opinion in immunology.
[170] David H. Miller,et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis , 2002, Annals of neurology.
[171] Michael D. Davis,et al. The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors* , 2002, The Journal of Biological Chemistry.
[172] Huub Schellekens,et al. Bioequivalence and the immunogenicity of biopharmaceuticals , 2002, Nature Reviews Drug Discovery.
[173] S. Sawcer,et al. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis , 2002, Journal of neurology, neurosurgery, and psychiatry.
[174] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[175] A. Castelló,et al. Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. , 2001, Journal of immunological methods.
[176] S. Grossberg,et al. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[177] A. Compston,et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.
[178] Marco Rovaris,et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study , 2001, The Lancet.
[179] M. Sela,et al. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone® , 2001, Journal of Neuroimmunology.
[180] Polman,et al. Drug treatment of multiple sclerosis , 2000, The Western journal of medicine.
[181] C Confavreux,et al. Relapses and progression of disability in multiple sclerosis. , 2000, The New England journal of medicine.
[182] S. Cole,et al. Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and early MS. Optic Neuritis Study Group. , 2000, Neurology.
[183] C. Eckert,et al. Expression analysis and characterization of alternatively spliced transcripts of human IL-7Ralpha chain encoding two truncated receptor proteins in relapsed childhood all. , 2000, Cytokine.
[184] K. Rajewsky,et al. Memory B-cell persistence is independent of persisting immunizing antigen , 2000, Nature.
[185] J H Simon,et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.
[186] J. Hillert,et al. HLA‐DR15 is associated with lower age at onset in multiple sclerosis , 2000, Annals of neurology.
[187] R. Mutani,et al. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. , 2000, Immunopharmacology.
[188] M. Reindl,et al. A comparative study of the relative bioavailability of different interferon beta preparations , 2000, Neurology.
[189] S. Cole,et al. Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and early MS , 2000, Neurology.
[190] À. Rovira,et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. , 2000, AJNR. American journal of neuroradiology.
[191] F. Heidenreich,et al. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS , 2000, Neurology.
[192] M. Hernán,et al. Geographic variation of MS incidence in two prospective studies of US women , 1999, Neurology.
[193] Stephen M. Rao,et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. , 1999, Brain : a journal of neurology.
[194] M. Reindl,et al. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies , 1999, Neurology.
[195] D. Paty,et al. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon β-1b , 1999, Neurology.
[196] R. Herndon,et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis , 1998, Neurology.
[197] R. Rudick,et al. Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.
[198] J. Petkau,et al. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis , 1997, Multiple sclerosis.
[199] G. Comi,et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. , 1997, Brain : a journal of neurology.
[200] R. Priore,et al. Mechanism(S) of interferon inhibitory activity in blood from patients with AIDS and patients with lupus erythematosus with vasculitis. , 1997, Research communications in molecular pathology and pharmacology.
[201] V. Perry,et al. Axonal damage in acute multiple sclerosis lesions. , 1997, Brain : a journal of neurology.
[202] C. Pozzilli,et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome , 1997, Journal of Neurology.
[203] L. Platanias,et al. Differences in interferon alpha and beta signaling. Interferon beta selectively induces the interaction of the alpha and betaL subunits of the type I interferon receptor. , 1996, The Journal of biological chemistry.
[204] D. Hinds,et al. A full genome search in multiple sclerosis , 1996, Nature Genetics.
[205] L Steinman,et al. Multiple Sclerosis: A Coordinated Immunological Attack against Myelin in the Central Nervous System , 1996, Cell.
[206] C. Granger,et al. Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.
[207] J. Kurtzke,et al. MS epidemiology world wide. One view of current status , 1995, Acta neurologica Scandinavica. Supplementum.
[208] A. Thompson,et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: Statistical power of parallel-groups and crossover designs , 1994, Journal of the Neurological Sciences.
[209] G J Barker,et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. , 1994, Brain : a journal of neurology.
[210] F. Finkelman,et al. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. , 1993, Journal of immunology.
[211] K. Melén,et al. Control of IFN-inducible MxA gene expression in human cells. , 1993, Journal of immunology.
[212] B E Kendall,et al. The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits. , 1991, Brain : a journal of neurology.
[213] A. Thompson,et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. , 1991, Journal of neurology, neurosurgery, and psychiatry.
[214] T. Taniguchi,et al. Organization of the murine and human interleukin-7 receptor genes: two mRNAs generated by differential splicing and presence of a type I-interferon-inducible promoter , 1991, Molecular and cellular biology.
[215] W. Mcdonald,et al. The longstanding MS lesion. A quantitative MRI and electron microscopic study. , 1991, Brain : a journal of neurology.
[216] O. Turriziani,et al. Neutralizing Antibodies to Interferon-α: Relative Frequency in Patients Treated with Different Interferon Preparations , 1991, The Journal of infectious diseases.
[217] D. Goodkin,et al. EDSS reliability , 1991, Neurology.
[218] B E Kendall,et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. , 1990, Brain : a journal of neurology.
[219] D. Li,et al. Chronic progressive multiple sclerosis: Serial magnetic resonance brain imaging over six months , 1989, Annals of neurology.
[220] B Bass,et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.
[221] D. Li,et al. Serial magnetic resonance scanning in multiple sclerosis: A second prospective study in relapsing patients , 1989, Annals of neurology.
[222] V. Kostulas,et al. Oligoclonal IgG bands in cerebrospinal fluid. Principles for demonstration and interpretation based on findings in 1114 neurological patients. , 1987, Archives of neurology.
[223] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[224] D. Silberberg,et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.
[225] P. Sehgal. The interferon genes. , 1982, Biochimica et biophysica acta.
[226] H. M. Baum,et al. The incidence and prevalence of reported multiple sclerosis , 1981, Annals of neurology.
[227] D. Burke,et al. Studies on the production, mode of action and properties of interferon. , 1957, British journal of experimental pathology.
[228] S. Gregory,et al. Cleavage and polyadenylation specificity factor 1 (CPSF1) regulates alternative splicing of interleukin 7 receptor (IL7R) exon 6. , 2013, RNA.
[229] H. Hartung,et al. Disease-Modifying Agents for Multiple Sclerosis , 2012, Drugs.
[230] E. Urcelay,et al. Validation of IRF5 as multiple sclerosis risk gene: putative role in interferon beta therapy and human herpes virus-6 infection , 2011, Genes and Immunity.
[231] O. Kantarci. Genotype–Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures , 2009 .
[232] O. Kantarci. HLA-DRB1*0401 and HLA-DRB1*0408 Are Strongly Associated with the Development of Antibodies against Interferon-β Therapy in Multiple Sclerosis , 2009 .
[233] S J Nelson,et al. Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. , 2009, Brain : a journal of neurology.
[234] D. Booth,et al. Haplotypes of the interleukin 7 receptor alpha gene are correlated with altered expression in whole blood cells in multiple sclerosis , 2008, Genes and Immunity.
[235] A. Verma. The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL , 2008 .
[236] L. Kappos,et al. Anti-interferon-beta neutralising activity is not entirely mediated by antibodies. , 2007, Journal of neuroimmunology.
[237] L. Kappos,et al. Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. , 2007, Journal of neurology.
[238] H. Harbo,et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. , 2007, Nature genetics.
[239] M. Ramanathan,et al. Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies. , 2006, Journal of neuroimmunology.
[240] K. Narayan,et al. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. , 2005, Journal of neuroimmunology.
[241] K. Shinohara,et al. Pure red-cell aplasia caused by the antibody to recombinant erythropoietin, epoetin-beta, in a Japanese patient with chronic renal failure. , 2005, American journal of hematology/oncology.
[242] R. Rudick,et al. Defining interferon beta response status in multiple sclerosis patients. , 2004, Annals of neurology.
[243] K. Zoon,et al. Human interferons alpha, beta and omega. , 2004, Growth factors.
[244] Hompson,et al. A LONGITUDINAL STUDY OF ABNORMALITIES ON MRI AND DISABILITY FROM MULTIPLE SCLEROSIS , 2002 .
[245] P. Gallo,et al. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. , 2001, European cytokine network.
[246] K. Bendtzen,et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. , 2000, Annals of neurology.
[247] D. Chitayat,et al. A partial deficiency of interleukin-7R alpha is sufficient to abrogate T-cell development and cause severe combined immunodeficiency. , 2000, Blood.
[249] A. Whitty,et al. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). , 1998, Pharmaceutical research.
[250] Jeffrey A. Cohen,et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. , 1995, Neurology.
[251] W. L. Benedict,et al. Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.